ArticleTranslational pediatrics2025
Global T-cell functionality evaluated by whole blood interferon-gamma release assay as a valuable indicator for immune reconstitution monitoring in pediatric allo-HSCT.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adequate T-cell immune reconstitution (IR) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is pivotal for the recovery and optimal outcomes of pediatric HSCT recipients. A thorough assessment of global T-cell functionality is a crucial component in monitoring T-cell IR during the post-transplant period. The purpose of this study is to provide a novel tool and strategy for assessing and monitoring T-cell IR after pediatric allo-HSCT. Methods: This study enrolled 126 pediatric patients receiving allo-HSCT at a single institution. A standardized whole blood interferon-gamma release assay (WB-IGRA) was introduced to evaluate global T-cell functionality in different periods after HSCT. Results: The study revealed that T-cell functionality, assessed via the WB-IGRA assay, progressively enhanced over the post-transplant period, effectively distinguishing between patients with and without immunosuppression, thereby highlighting the assay's viability in assessment of T-cell IR in children after allo-HSCT. Further analysis stratified by age revealed a more significant enhancement in T-cell functionality among children >10 years old compared to those ≤10. Conversely, when evaluating immune cell subsets, increases in CD3 Conclusions: This study demonstrated the potential application of the WB-IGRA approach in evaluating and monitoring T-cell IR in pediatric allo-HSCT recipients. Combining the assessment of T-cell immune functionality with cellular phenotypes could enhance the understanding of T-cell IR in HSCT children of different ages.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.